Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck

Serum concentrations of Cyfra 21-1, a soluble cytokeratin fragment, were evaluated in 157 healthy patients, 66 patients with benign ear, nose or throat disease, and 102 patients with untreated epidermoid carcinoma of the head and neck. The technique had a sensitivity of 53.9% and specificity of 98.4...

Full description

Saved in:
Bibliographic Details
Published inActa otorrinolaringológica española Vol. 50; no. 2; p. 85
Main Authors González Sánchez, E, López-Ríos Velasco, J, Calvo Boizas, E, García-Talavera Fernández, J R, Martín Ro-dríguez, M, Muñoz Herrera, A, Del Cañizo Alvarez, A
Format Journal Article
LanguageSpanish
Published Spain 01.03.1999
Subjects
Antigens, Neoplasm - blood
Biomarkers, Tumor - blood
Carcinoma, Squamous Cell - blood
Carcinoma, Squamous Cell - diagnosis
Head and Neck Neoplasms - blood
Head and Neck Neoplasms - diagnosis
Humans
Keratin-19
Keratins
Sensitivity and Specificity
Online AccessGet more information

Cover

More Information
Summary:Serum concentrations of Cyfra 21-1, a soluble cytokeratin fragment, were evaluated in 157 healthy patients, 66 patients with benign ear, nose or throat disease, and 102 patients with untreated epidermoid carcinoma of the head and neck. The technique had a sensitivity of 53.9% and specificity of 98.4% for a cutoff value of 1.5 ng/ml. Cyfra 21-1 levels differed significantly with tumor location (p < 0. 005) and tumor stage (p < 0.005), but not with the degree of histological differentiation.
ISSN:0001-6519